Peritoneal sarcomatosis from uterine sarcoma is a rare disease with no effective treatment and poor prognosis. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has successful results in peritoneal carcinomatosis from gastrointestinal/gynecological origins. We show that CRS/HIPEC is safe, feasible, and may benefit selected patients with peritoneal sarcomatosis from uterine sarcoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986004 | PMC |
| http://dx.doi.org/10.1002/ccr3.1491 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Review of Imaging Peritoneal Disease and Treatment.
Can Assoc Radiol J
December 2024
Abdominal Division, Joint Department of Medical Imaging, Toronto, ON, Canada.
Article Synopsis
- Peritoneal disease is divided into benign and malignant categories, with malignant cases further classified into primary and secondary types, including conditions like peritoneal mesothelioma and peritoneal carcinomatosis.
- Differentiating between benign and malignant peritoneal conditions is crucial, as this determines the course of treatment and helps avoid unnecessary procedures.
- For patients with secondary malignant diseases like peritoneal carcinomatosis, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) may offer a chance for cure, and radiologists play a key role in assessing disease extent and potential surgical issues.
A comparative in vivo study of hyperthermic intraperitoneal chemotherapy with cisplatin versus doxorubicin versus cisplatin plus doxorubicin for the treatment of intra-abdominally disseminated alveolar rhabdomyosarcoma in mice.
Pediatr Blood Cancer
December 2024
Department of Pediatric Surgery and Urology, University Hospital Giessen-Marburg, Marburg, Germany.
Article Synopsis
- Treatment for advanced pediatric rhabdomyosarcoma with peritoneal sarcomatosis involves a combination of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC), but the ideal drug dosages and combinations have not been well-studied.
- An in vivo mouse model was created to test the efficacy of different doses of cisplatin and doxorubicin in HIPEC, finding that certain dosages significantly reduced the extent of tumor spread, indicated by the peritoneal cancer index (PCI).
- Results showed that a combination of lower doses of both drugs had the best effect on reducing tumor spread, suggesting that further research is needed to fully understand the treatment's impact and improve strategies.
Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Peritoneal Sarcomatosis.
Cancers (Basel)
August 2024
Department of General, Visceral and Transplant Surgery, University Hospital Tübingen, Hoppe-Seyler-Str. 3, 72076 Tübingen, Germany.
(1) Background: Cytoreductive surgery (CRS) with HIPEC is considered the standard of care for selected patients with peritoneal carcinomatosis, but evidence-based treatment recommendations for the therapy of peritoneal sarcomatosis are scarce. (2) Methods: We retrospectively analyzed all adult patients treated with CRS and HIPEC for peritoneal sarcomatosis between 2017 and 2024. (3) Results: Ten patients with a median age of 46.
View Article and Find Full Text PDFIbero-American Consensus for the Management of Peritoneal Sarcomatosis: Updated Review and Clinical Recommendations.
Cancers (Basel)
July 2024
Hepatobiliary Surgery and Liver Transplant Unit, Gregorio Marañón University Hospital, 28007 Madrid, Spain.
Peritoneal sarcomatosis is a rare malignant disease with a poor prognosis, secondary to peritoneal dissemination of abdominopelvic soft tissue sarcomas. Its rarity, together with the characteristic histological heterogeneity and the historically poor response to systemic treatments, has prevented the establishment of widely accepted treatment criteria with curative intent. In this sense, radical cytoreductive surgery (CRS) with peritonectomy procedures and hyperthermic intraperitoneal chemotherapy (HIPEC), widely used in peritoneal carcinomatosis with excellent results, have not had the same evolutionary development in patients with peritoneal sarcomatosis.
View Article and Find Full Text PDFRadical cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal sarcomatosis: Results from a reference center and considerations based on current evidence.
Cir Esp (Engl Ed)
August 2024
Sección Tumores Mesenquimales y Sarcomas de la Asociación Española de Cirujanos (AEC), Madrid, Spain; Servicio de Cirugía General y del Aparato Digestivo, CSUR de Sarcomas y Tumores Músculo-Esqueléticos, Hospital Universitario Gregorio Marañón, Madrid, Spain.
Introduction: Peritoneal sarcomatosis is a rare disease, with multiple histological origins and poor overall prognosis. The option of radical cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is controversial. The results of a surgical team experienced in these procedures are analyzed and discussed based on the available evidence.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!